Pfizer Misses Q4 Earnings Forecast as UpJohn, Lyrica Revenues Slide

Pfizer said sales of its Lyrica pain treatment, which lost patent protection last year, fell by more than two thirds, clipping overall group revenues ahead of the combination of its generic branded drugs division with Mylan.